FOXO4-DRI
LONGEVITYQuick Specifications
| Vial Size | 5MG |
|---|---|
| BAC Water | 2ML |
| Amount Per Unit | 0.025MG PER UNIT |
| Recommended Dose | 100MCG TO 500MCG (4 TO 20 UNITS) |
| Frequency | 3 TIMES PER WEEK FOR 3 WEEKS (1-2X ANNUALLY) |
| Injection Type | SUBCUTANEOUS |
| Timing | Every other day, 3x/week for 3 weeks per cycle. 1-2 cycles per year. Allow 4-6 weeks post-cycle for cellular clearance effects. Benefits are cumulative and emerge over weeks to months. Commonly studied alongside Epithalon for the longevity-focused protocol. Store at -20C before reconstitution; use within 30 days once reconstituted. |
Research Overview
FOXO4-DRI (FOXO4 D-Retro-Inverso) is the most researched peptide senolytic — a compound that selectively induces apoptosis in senescent cells by blocking the FOXO4-p53 pro-survival interaction. Senescent cells are cells that have permanently stopped dividing but remain metabolically active, secreting pro-inflammatory SASP (Senescence-Associated Secretory Phenotype) compounds including IL-6, TNF-alpha, and matrix metalloproteinases that accelerate aging in surrounding tissue. FOXO4-DRI disrupts the FOXO4-p53 complex specifically in senescent cells (which upregulate FOXO4 to resist apoptosis), restoring p53's pro-apoptotic function and triggering selective senescent cell death while leaving healthy cells intact. The landmark 2017 Nature paper by Baar et al. demonstrated measurable rejuvenation phenotypes in naturally aged mice following treatment. A 2025 Nature Communications study confirmed the mechanism at atomic resolution. The D-retro-inverso modification uses D-amino acids in reversed sequence, creating resistance to proteolytic degradation and extending half-life. FOXO4-DRI is studied in longevity protocols alongside Epithalon, and senolytics research often pairs it with navitoclax or dasatinib for complementary BCL-2 pathway targeting. For research and educational purposes only.
Commonly Studied With
These peptides are frequently researched alongside FOXO4-DRI: 5mg due to complementary mechanisms:
For research-grade FOXO4-DRI with third-party Certificate of Analysis documentation, Peptide Hub recommends Apollo Peptide Sciences. Apollo Peptide Sciences carries FOXO4-DRI as part of their longevity research catalog. Affiliate disclosure: we may earn a commission on purchases through this link.
FOXO4-DRI: 5mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: 100MCG TO 500MCG (4 TO 20 UNITS)